title: [CD20-positive peripheral T-cell lymphoma, not otherwise specified].
abstract: We report a 69-year-old male with CD3-positive peripheral T-cell lymphoma, not otherwise specified (PTCL-nos). Interestingly, tumor cells slightly expressed CD20 as well. Southern analyses of the tumor cells showed rearrangement for only the T cell receptor gene but not the immunoglobulin genes. This patient achieved partial remission with a treatment regimen of THP-COP excluding prednisolone, but died of pneumonia. Although CD20-positive PTCL is rare, a review of the reported cases suggests that CD20-positive PTCL has a poor prognosis and that bone marrow infiltration of tumor cells results in a poorer prognosis in CD20-positive PTCL than in usual PTCL. By accumulating cases of this rare entity of lymphoma, we need to clarify the biological nature of the tumor cells and usefulness of rituximab combined with standard chemotherapy.
authors.affiliation: Department of Hematology and Oncology, Dokkyo Medical University School of Medicine.
authors.forename: Honoka
authors.initials: H
authors.lastname: Arai
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Maki
authors.forename: Jiro
authors.initials: J
authors.lastname: Tadokoro
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Handa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Shigeharu
authors.initials: S
authors.lastname: Tsurumi
authors.forename: Ko
authors.initials: K
authors.lastname: Sasaki
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D018951:Antigens, CD20; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017809:Fatal Outcome; D005434:Flow Cytometry; D015321:Gene Rearrangement; D005820:Genetic Testing; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D011948:Receptors, Antigen, T-Cell; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone